Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable

Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer

Study Showing Objective Tumor Response or Stable Disease -

CHICAGO and TUSTIN, Calif., June 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing. The Phase I study results also showed that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and that the pharmacokinetic properties of bavituximab were not impacted by co- administration with conventional chemotherapies.

Separately, Peregrine reported an update from its ongoing Phase II trial evaluating bavituximab plus docetaxel in advanced breast cancer. Enrollment of an initial group of 15 patients in the two-stage Phase II study was recently completed. Of the 11 evaluable patients to date, none have experienced any measureable tumor growth or disease progression, with five of the 11 evaluable patients achieving a partial tumor response. All enrolled patients are continuing to receive treatment and are being evaluated regularly for tumor response according to RECIST criteria. The primary objective of the multi-center, open
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... at the University of California, San Diego for a ... load bearing Gravitic™ MRI (Magnetic Resonance Imaging) with that ... renowned for its continued pursuit of improved healthcare by ... Spinal MRI is an extremely valuable tool for evaluating ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 PathoGenetix, Inc., ... bacterial strain typing, announced today that it has successfully ... E. coli strains obtained from the Centers for Disease ... Scanning™ (GSS™) technology. The findings are detailed in a ... the American Society for Microbiology in Denver on Monday. ...
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... , May 20, 2013  MiMedx Group, Inc. ... and marketer of patent protected regenerative biomaterials and bioimplants ... has secured a revolving line of credit with Bank ... is secured by the Company,s accounts receivable and inventory, ... May 1, 2014.  The facility will be used for ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... cells have been touted as a cleaner solution to ... cars to computers. But one reason fuel ... endurance. Over time, the catalysts used even in today,s ... that converts fuel into electricity. In addition, current technology ...
... YORK, March 31, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p096374/Molecular-Diagnostics-Markets.html The technologies that ... fluorescent in situ hybridization (FISH), second-generation biochips ...
... MOUNTAIN VIEW, Calif., March 31, 2011 Clontech Laboratories, Inc., ... launch of its SMARTer Ultra Low RNA Kit for ... Inc. This kit uses a modified version of Clontech,s patented ... to facilitate transcriptome analysis from as little as 100 pg ...
Cached Biology Technology:Novel nanowires boost fuel cell efficiency 2Reportlinker Adds Molecular Diagnostics Markets 2Reportlinker Adds Molecular Diagnostics Markets 3Reportlinker Adds Molecular Diagnostics Markets 4Reportlinker Adds Molecular Diagnostics Markets 5Reportlinker Adds Molecular Diagnostics Markets 6Reportlinker Adds Molecular Diagnostics Markets 7Reportlinker Adds Molecular Diagnostics Markets 8Reportlinker Adds Molecular Diagnostics Markets 9Reportlinker Adds Molecular Diagnostics Markets 10Reportlinker Adds Molecular Diagnostics Markets 11Reportlinker Adds Molecular Diagnostics Markets 12Reportlinker Adds Molecular Diagnostics Markets 13Reportlinker Adds Molecular Diagnostics Markets 14Reportlinker Adds Molecular Diagnostics Markets 15Reportlinker Adds Molecular Diagnostics Markets 16Reportlinker Adds Molecular Diagnostics Markets 17Reportlinker Adds Molecular Diagnostics Markets 18Clontech Laboratories, Inc. Releases the SMARTer™ Ultra Low RNA Kit for Illumina® Sequencing 2Clontech Laboratories, Inc. Releases the SMARTer™ Ultra Low RNA Kit for Illumina® Sequencing 3
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...
(Date:5/21/2013)... Illinois at Chicago College of Medicine will study gender differences ... main energy source -- and how changes in fat metabolism ... million, 4-year grant from the National Heart, Lung and Blood ... fuel for energy. These changes may play a major role ... men and women, says E. Douglas Lewandowski, director of the ...
Breaking Biology News(10 mins):Keeping stem cells strong 2MU researchers develop radioactive nanoparticles that target cancer cells 2Do men's and women's hearts burn fuel differently? 2
... ship hulls with artificial shark skin could help ships ... barnacles on ship hulls is a major cause of ... offers a structural design that prevents this so called ... Sciences, Bremen, Germany, is presenting his work on the ...
... a cliff. Another prefers to read a book and ... is a mystery, but for the first time researchers ... , Scientists at Fred Hutchinson Cancer Research Center ... is related to the development of an almond-shaped area ...
... hulls with artificial shark skin could help ships sailing ... on ship hulls is a major cause of increased ... a structural design that prevents this so called 'bio-fouling'. ... Bremen, Germany, is presenting his work on the application ...
Cached Biology News:Study identifies gene in mice that may control risk-taking behavior in humans 2Study identifies gene in mice that may control risk-taking behavior in humans 3
Animal Origin Free...
IHC Detection Kit (Broad Spectrum AEC)....
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Biology Products: